Gland Pharma Limited received FDA approval for its ophthalmic solution containing Brimonidine Tartrate and Timolol Maleate, marking a strategic expansion of its generic portfolio. The approval is expected to heighten competitive pricing pressure in the glaucoma treatment sector as the product becomes commercially available later this year.